Literature DB >> 66216

Effects of a new glucocorticoid, oxazacort, on some variables connected with bone metabolism in man: a comparison with prednisone.

A Caniggia, M Marchetti, C Gennari, A Vattimo, F B Nicolis.   

Abstract

The urinary elimination of calcium, other electrolytes, and hydroxyproline and the oral absorption of 47Ca have been evaluated in three groups of 8 patients before and during a 15-day treatment with prednisone at daily doses of 25 and 50 mg and with oxazacort, a new glucocorticoid, at a daily dose of 50 mg. The results obtained demonstrate that oxazacort in short-term teatment with a high dose has no significant effect on the urinary elimination of calcium and hydroxypyroline in experimental conditions in which prednisone produces statistically significant and clinically relevant increase, both when given at the same dose and when given at half that dose. On the other hand, the oral absorption of 47Ca is decreased by oxazacort, but less than by prednisone at the same dose. As the antirheumatic activity of oxazacort appears to be only slightly lower than that of prednisone (activity ratio of about 0.84: 1), these findings may have interesting therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 66216

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Biopharm        ISSN: 0340-0026


  11 in total

1.  Effects of prednisone and deflazacort on vertebral bone mass.

Authors:  C Gennari; B Imbimbo
Journal:  Calcif Tissue Int       Date:  1985-12       Impact factor: 4.333

2.  Bone loss after glucocorticoid therapy.

Authors:  V Lo Cascio; E Bonucci; B Imbimbo; P Ballanti; D Tartarotti; G Galvanini; L Fuccella; S Adami
Journal:  Calcif Tissue Int       Date:  1984-07       Impact factor: 4.333

3.  Comparison of subacute effects of oxazacort and prednisone on mineral metabolism in man.

Authors:  T J Hahn; L R Halstead; B Strates; B Imbimbo; D T Baran
Journal:  Calcif Tissue Int       Date:  1980       Impact factor: 4.333

4.  Effects of long-term maintenance therapy with a new glucocorticoid, deflazacort, on mineral metabolism and statural growth.

Authors:  S Balsan; D Stéru; A Bourdeau; R Grimberg; G Lenoir
Journal:  Calcif Tissue Int       Date:  1987-06       Impact factor: 4.333

5.  Serum osteocalcin (bone Gla-protein) following corticosteroid therapy in postmenopausal women with rheumatoid arthritis. Comparison of the effect of prednisone and deflazacort.

Authors:  C Montecucco; F Baldi; A Fortina; G Tomassini; R Caporali; E L Cherie-Ligniere; P Fratino
Journal:  Clin Rheumatol       Date:  1988-09       Impact factor: 2.980

6.  Effects of prednisone and deflazacort on mineral metabolism and parathyroid hormone activity in humans.

Authors:  C Gennari; B Imbimbo; M Montagnani; M Bernini; P Nardi; L V Avioli
Journal:  Calcif Tissue Int       Date:  1984-05       Impact factor: 4.333

7.  Disposition of a new steroidal anti-inflammatory agent, deflazacort, in rat, dog and man.

Authors:  A Alessandro; P Antonio; B Giuseppe; P Valeria
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1980       Impact factor: 2.441

8.  Comparative study of deflazacort, a new synthetic corticosteroid, and dexamethasone on the synthesis of collagen in different rat bone cell populations and rabbit articular chondrocytes.

Authors:  H L Guenther; R Felix; H Fleisch
Journal:  Calcif Tissue Int       Date:  1984-03       Impact factor: 4.333

9.  Acute effect of prednisone and deflazacort on glucose tolerance in prediabetic subjects.

Authors:  G Pagano; A Lombardi; G M Ferraris; B Imbimbo; P Cavallo Perin
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

10.  25-Hydroxycholecalciferol as an antagonist of adverse corticosteroid effects on phosphate and calcium metabolism in man.

Authors:  R Nuti; A Vattimo; V Turchetti; G Righi
Journal:  J Endocrinol Invest       Date:  1984-10       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.